CSF3 and non-small cell lung carcinoma: A feasibility and efficacy study of dose intensification of cisplatin and epirubicin in patients with relapsed NSCLC demonstrated that epirubicin can be escalated to 135 mg m−2 every 2 weeks provided that granulocyte-colony stimulating factor (G-CSF) support was added to prevent severe myelosuppression (Huisman et al, 2001).